Scientific image

Research & Development



As researchers, we are passionate about scientific excellence because what we do today may improve the lives of people tomorrow. We work to transform scientific knowledge and medical advances into cutting-edge therapies to improve people’s lives worldwide. Discovering solutions for the world’s most pressing medical needs is our top priority.

Our R&D community is made up of scientists, physicians, technicians, product and manufacturing engineers and world-class innovators, all of whom contribute to our scientific leadership. Our goal is breakthrough innovation that can transform, extend and potentially save lives. 

As people live longer, chronic conditions are on the rise. New viruses and diseases are emerging, while old enemies like cancer and neurodegenerative diseases remain. Sanofi is driven by the scope of these health challenges.

Innovative approaches

To unlock tomorrow’s science to develop the latest treatments, Sanofi’s R&D community is: 

  • investing in multi-targeting therapies to tackle multiple diseases with a single drug;
  • working on combination therapies to make treatments more effective;
  • developing new biologics to produce precision medicines;
  • conducting breakthrough research to unlock the potential of gene therapy;
  • leveraging artificial intelligence and innovative digital technologies to empower patients to better manage chronic conditions.
A woman scientist working in research and development

R&D portfolio

At the end of July 2019, the R&D pipeline contained 83 projects including 34 new molecular entities in clinical development. 35 projects are in phase 3 or have been submitted to the regulatory authorities for approval.

Research areas

Sanofi is investing in five research areas to find innovative solutions for unmet needs:

Scientific image

Oncology

Despite incredible progress by scientists and drug developers over the last 20 years, cancer remains the second leading cause of death worldwide. At Sanofi, we are combining our extensive heritage in small molecule research with new biologic capabilities to move cancer therapy forward. That means matching the right approach to the right patient, advancing the complementary approaches of molecular oncology and immunotherapy. To achieve this, we’re leveraging multiple technology platforms, including monoclonal antibodies, messenger RNA (mRNA), and antibody drug conjugates - antibodies that are used as a unique delivery system to deliver drugs to where they are needed to combat cancer in the body.
Scientific image

Immunology & Inflammation

We understand the serious daily challenges that people with immune-mediated diseases face. In recent years, we have led the science in immunology by introducing new treatment options for chronic, difficult-to-treat inflammatory diseases such as atopic dermatitis (eczema), asthma and rheumatoid arthritis (RA). We are applying the most advanced research technologies and are focused on inflammatory conditions and autoimmune diseases with the highest unmet need. One of our key approaches is to develop multi-specific antibody therapies that combine multiple mechanisms of action in a single molecule and that target two or more molecular pathways simultaneously. We hope that these new therapies will become transformative treatments for the millions of patients suffering from immune-mediated diseases.
Scientific image

Rare Blood Disorders

With Ablynx and Bioverativ joining the Sanofi family, we are now spearheading an industry-leading franchise to treat rare blood disorders. We continue to build on our legacy of innovation, from the development of the first extended half-life clotting factors for treating hemophilia A and B, using a range of technologies including further engineering clotting factor fusion proteins, small interfering RNA (siRNA) and gene therapy. We are using our proprietary Nanobody® platform to develop the potential first-ever treatment option for acquired Thrombotic Thrombocytopenic Purpura (aTTP), a life threatening blood clotting disorder. We are developing novel therapies using our insights into the complement mediated pathophysiology of other rare blood disorders, such as cold agglutinin disease, a chronic autoimmune hemolytic condition for which there are no approved therapies. We are also working to address the significant unmet medical need in sickle cell disease and other hemoglobinopathies with both small molecule and ex vivo gene editing approaches.
Scientific image

Rare and Neurologic Diseases

We are committed to developing transformative therapies for patients with rare and neurologic diseases. Our expertise has led to pioneering medicines for rare lysosomal storage disorders such as Fabry, Gaucher and Pompe diseases, as well as disease modifying therapies for Multiple Sclerosis. Our research has advanced novel approaches to treat rare kidney diseases and neurodegenerative diseases such as Parkinson's disease associated with glucocerebrosidase (GBA) gene mutations to clinical trials. A cornerstone of our efforts includes developing gene therapies for inherited neurologic, ophthalmologic, metabolic and lysosomal storage disorders.
Scientific image

Diabetes & Cardiovascular (DCV)

For decades, Sanofi has led the way in developing innovative treatments for diabetes – and we continue to introduce new innovations in this area. At the same time, there is growing awareness of the multiple connections between diabetes and cardiovascular (DCV) diseases, and the role of obesity in driving them both. Today, our innovative research in DCV is focused on developing new therapeutics that address the underlying causes of DCV diseases, key co-morbidities of diabetes, and diseases with similar biology. In this quest, we are focused on developing innovative technology platforms, such as triple-agonistic peptides – multi-targeting therapies that could hold the key to controlling and reversing obesity, and its consequences.